Amino Acids

, Volume 46, Issue 2, pp 311–319

Detection of diabetic nephropathy from advanced glycation endproducts (AGEs) differs in plasma and urine, and is dependent on the method of preparation

  • Paul J. Beisswenger
  • Scott K. Howell
  • Greg Russell
  • Michael E. Miller
  • Stephen S. Rich
  • Michael Mauer
Original Article


Increased advanced glycation endproducts (AGEs) and oxidation products (OPs) have been proposed as pathogenic for diabetic nephropathy (DN). We investigated the relationship between AGEs and OPs measured in different plasma and urine preparations, and progression of DN in 103 young, normoalbuminuric, normotensive participants with type 1 diabetes in the Natural History of Diabetic Nephropathy Study. The primary endpoint was electron microscopy-measured change in glomerular basement membrane (GBM) width from baseline to 5 years; change in mesangial fractional volume was a secondary endpoint. Fast progressors (FP) were defined as the upper quartile (n = 24) of rate of GBM thickening; slow progressors (SP) were the remainder (n = 79). Four AGEs [3-deoxyglucosone and methylglyoxal hydroimidazolones (DG3H1, MGH1) and carboxymethyl and ethyl lysine (CML, CEL)], and two oxidation products methionine sulfoxide and aminoadipic acid were measured by liquid chromatography, triple quadrupole mass spectrometry. Measurements were done on 10 K plasma filtrates and plasma proteolytic digests (PPD) at year 5, and at four time points over 5 years for urinary 10 K filtrates. Urinary filtrate CEL levels were significantly higher in FP, but not after adjustment for HbA1c, sex, and duration of diabetes. MGHI, CEL, and CML plasma filtrate levels were significantly higher in FP relative to SP (p < 0.05). In PPD, only MGHI showed borderline significantly higher levels in FP relative to SP (p = 0.067), while no other product showed correlation. AGE and OP measurements were not correlated with mesangial expansion. In plasma filtrates, HbA1c at year 5 accounted for 4.7 % of the variation in GBM width. The proportion of variation in GBM width was increased to 11.6 % when MGHI, CEL, and CML were added to the model (6.9 % increase).


Diabetic nephropathy Diabetic complications Advanced glycation endproducts Oxidation end-products Glycation Oxidation Biomarkers Mass spectrometry 


  1. Ahmed N, Babaei-Jadidi R, Howell S, Beisswenger P, Thornalley P (2005a) Degradation products of proteins damaged by glycation, oxidation and nitration in clinical type 1 diabetes. Diabetologia 48:1590–1603PubMedCrossRefGoogle Scholar
  2. Ahmed N, Babaei-Jadidi R, Howell S, Thornalley P, Beisswenger P (2005b) Glycated and oxidised protein degradation products are indicators of fasting and postprandial hyperglycemia in diabetes. Diabetes Care 28:2465–2471PubMedCrossRefGoogle Scholar
  3. Andersen AR, Christiansen JS, Andersen JK, Kreiner S, Deckert T (1983) Diabetic nephropathy in type 1 (insulin-dependent) diabetes: an epidemiological study. Diabetologia 25(6):496–501PubMedCrossRefGoogle Scholar
  4. Beisswenger P (2012) Glycation and biomarkers of vascular complications of diabetes. Amino Acids Glycation 42:1171–1183CrossRefGoogle Scholar
  5. Beisswenger P, Howell S, O’Dell R, Wood M, Touchette A, Szwergold B (2001) Alpha dicarbonyls increase in the postprandial period and reflect the degree of hyperglycemia. Diabetes Care 24:726–732PubMedCrossRefGoogle Scholar
  6. Beisswenger P, Drummond K, Nelson R, Howell S, Szwergold B, Mauer M (2005) Susceptibility to diabetic nephropathy is related to dicarbonyl and oxidative stress. Diabetes 54:3274–3281PubMedCrossRefGoogle Scholar
  7. Beisswenger P, Howell S, Szwergold B, Rich S, Russell G, Kim Y, Mauer M (2008) Progression of diabetic nephropathy is predicted by increased oxidative stress and decreased deglycation. Diabetologia 51(Suppl1):S24Google Scholar
  8. Brownlee M (2005) The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54(6):1615–1625PubMedCrossRefGoogle Scholar
  9. Caramori ML, Fioretto P, Mauer M (2000) The need for early predictors of diabetic nephropathy risk: is albumin excretion rate sufficient? [Review] [91 refs]. Diabetes 49(9):1399–1408PubMedCrossRefGoogle Scholar
  10. Caramori ML, Kim Y, Huang C, Fish AJ, Rich SS, Miller ME, Russell G, Mauer M (2002) Cellular basis of diabetic nephropathy: 1. Study design and renal structural-functional relationships in patients with long-standing type 1 diabetes. [Erratum appears in diabetes 2002 Apr; 51(4):1294]. Diabetes 51(2):506–513PubMedCrossRefGoogle Scholar
  11. Cefalu WT (2008) Glycemic targets and cardiovascular disease. N Engl J Med 358(24):2633–2635PubMedCrossRefGoogle Scholar
  12. Ceriello A, Hanefeld M, Leiter L, Monnier L, Moses A, Owens D, Tajima N, Tuomilehto J (2004) Postprandial glucose regulation and diabetic complications. [Review] [58 refs]. Arch Intern Med 164(19):2090–2095PubMedCrossRefGoogle Scholar
  13. DCCT Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Eng J Med 329(14):977–986CrossRefGoogle Scholar
  14. DCCT Research Group (1997) Clustering of long-term complications in families with diabetes in the diabetes control and complications trial. Diabetes 46:1829–1839CrossRefGoogle Scholar
  15. DCCT/EDIC Complications Research Group (2002) Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. Jama 287(19):2563–2569CrossRefGoogle Scholar
  16. Dluhy RG, McMahon GT (2008) Intensive glycemic control in the ACCORD and ADVANCE trials. N Engl J Med 358(24):2630–2633PubMedCrossRefGoogle Scholar
  17. Drexel H, Klocker H, Patsch JR, Breier C, Braunsteiner H (1987) Measurement of glycated protein by a rapid and specific method for absolute quantification of lysine-bound glucose. Clin Chem 339:1656–1659Google Scholar
  18. Drummond K, Mauer M, International Diabetic Nephropathy Study Group (2002) The early natural history of nephropathy in type 1 diabetes: II. Early renal structural changes in type 1 diabetes. Diabetes 51(5):1580–1587PubMedCrossRefGoogle Scholar
  19. Drummond KN, Kramer MS, Suissa S, Levy-Marchal C, Dell’Aniello S, Sinaiko A, Mauer M, G. International Diabetic Nephropathy Study (2003) Effects of duration and age at onset of type 1 diabetes on preclinical manifestations of nephropathy. Diabetes 52(7):1818–1824PubMedCrossRefGoogle Scholar
  20. Fioretto P, Steffes MW, Mauer M (1994) Glomerular structure in nonproteinuric IDDM patients with various levels of albuminuria. Diabetes 43(11):1358–1364PubMedCrossRefGoogle Scholar
  21. Fioretto P, Steffes MW, Barbosa J, Rich SS, Miller ME, Mauer M (1999) Is diabetic nephropathy inherited? Studies of glomerular structure in type 1 diabetic sibling pairs. Diabetes 48(4):865–869PubMedCrossRefGoogle Scholar
  22. Goldberg AL (2003) Protein degradation and protection against misfolded or damaged proteins. [Review] [45 refs]. Nature 426(6968):895–899PubMedCrossRefGoogle Scholar
  23. Krolewski AJ, Warram JH, Kahn R, Kahn LI, Kahn CR (1987) Epidemiologic approach to the etiology of type I diabetes mellitus and its complications. N Eng J Med 18:267–273Google Scholar
  24. Malencik D, Sprouse J, Swanson C, Anderson S (1996) Dityrosine: preparation, isolation, and analysis. Anal Biochem 242:202–213PubMedCrossRefGoogle Scholar
  25. Mauer M, Zinman B, Gardiner R, Suissa S, Sinaiko A, Strand T, Drummond K, Donnelly S, Goodyer P, Gubler MC, Klein R (2009) Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 361(1):40–51PubMedCentralPubMedCrossRefGoogle Scholar
  26. Mogensen CE, Christensen C (1984) Predicting diabetic nephropathy in insulin-dependent patients. N Engl J Med 311:89–93PubMedCrossRefGoogle Scholar
  27. Monnier L, Colette C (2006) Contributions of fasting and postprandial glucose to hemoglobin A1c. [Review] [20 refs]. Endocr Pract 1:42–46CrossRefGoogle Scholar
  28. Monnier VM, Sell DR, Genuth S (2005) Glycation products as markers and predictors of the progression of diabetic complications. [Review] [78 refs]. Ann N Y Acad Sci 1043:567–581PubMedCrossRefGoogle Scholar
  29. Perkins BA, Krolewski AS (2009) Early nephropathy in type 1 diabetes: the importance of early renal function decline. Curr Opin Nephrol Hypertens 18(3):233–240PubMedCentralPubMedCrossRefGoogle Scholar
  30. Pettitt D, Saad M, Bennett P, Nelson R, Knowler W (1990) Familial predisposition to renal disease in two generations of Pima Indians with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 33(7):438–443PubMedCrossRefGoogle Scholar
  31. Prager TC, Wilson DJ, Avery GD (1981) Vitreous fluorophotometry: identification of sources of variability. Invest Ophthalmol Vis Sci 21:854–864PubMedGoogle Scholar
  32. Rohlfing CL, Wiedmeyer HM, Little RR, England JD, Tennill A, Goldstein DE (2002) Defining the relationship between plasma glucose and HbA(1c): analysis of glucose profiles and HbA(1c) in the diabetes control and complications trial. Diabetes Care 25(2):275–278PubMedCrossRefGoogle Scholar
  33. Roper J, McIlwain H (1948) Preparation and antibacterial action of some compounds structurally related to glutamic acid their applications in microbiological determinations of small quantities of glutamine. Biochem J 42:485–492PubMedGoogle Scholar
  34. Seaquist ER, Goetz FC, Rich S, Barbosa J (1989) Familial clustering of diabetic kidney disease: evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med 320:1161–1165PubMedCrossRefGoogle Scholar
  35. Steinke JM, Sinaiko AR, Kramer MS, Suissa S, Chavers BM, Mauer M (2005) The early natural history of nephropathy in type 1 diabetes: III. Predictors of 5-year urinary albumin excretion rate patterns in initially normoalbuminuric patients. Diabetes 54(7):2164–2171PubMedCrossRefGoogle Scholar
  36. Thornalley PJ, Battah S, Ahmed N, Karachalias N, Agalou S, Babaei-Jadidi R, Dawnay A (2003) Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry. Biochem J 375(Pt 3):581–592PubMedCrossRefGoogle Scholar
  37. Turner RC, Cull CA, Frighi V, Holman RR (1999) Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 281(21):2005–2012PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 2013

Authors and Affiliations

  • Paul J. Beisswenger
    • 1
    • 2
  • Scott K. Howell
    • 2
  • Greg Russell
    • 3
  • Michael E. Miller
    • 3
  • Stephen S. Rich
    • 4
  • Michael Mauer
    • 5
  1. 1.Section of Diabetes, Endocrinology, and MetabolismDartmouth-Hitchcock Medical CenterLebanonUSA
  2. 2.Department of Medicine/EndocrinologyGeisel School of Medicine at DartmouthHanoverUSA
  3. 3.Department of Biostatistical SciencesWake Forest UniversityWinston-SalemUSA
  4. 4.Center for Public Health GenomicsUniversity of VirginiaCharlottesvilleUSA
  5. 5.Department of Pediatrics and MedicineUniversity of MinnesotaMinneapolisUSA

Personalised recommendations